Growth Metrics

Sarepta Therapeutics (SRPT) EBT Margin (2012 - 2026)

Sarepta Therapeutics' quarterly EBT Margin came in at 85.73% in Q1 2026, up 37337.0% year-on-year from N/an in Q1 2025, and up 236.45% quarter-over-quarter from 62.83% in Q4 2025.

Sarepta Therapeutics has reported EBT Margin for 13 years, with the latest figure at 85.73% in Q1 2026.

  • For the quarter ending Q1 2026, EBT Margin rose 37337.0% year-over-year to 85.73%; the trailing twelve-month figure through Mar 2026 stood at 1.32% (up 1712.0% YoY), and the FY2025 full-year result was 31.94%, down 4081.0% from the prior year.
  • EBT Margin for Q1 2026 stood at 85.73%, up from 62.83% in the prior quarter.
  • The five-year high for EBT Margin was 199.35% in Q4 2022, with the low at 473.28% in Q1 2022.
  • Average EBT Margin over 5 years is 57.53%, with a median of 10.0% recorded in 2023.
  • Year-over-year, EBT Margin plunged 35936 bps in 2022 and jumped 37337 bps in 2026.
  • Tracing SRPT's EBT Margin over 5 years: stood at 199.35% in 2022, then tumbled by 70 bps to 60.2% in 2023, then slumped by 80 bps to 12.1% in 2024, then plunged by 619 bps to 62.83% in 2025, then soared by 236 bps to 85.73% in 2026.
  • The last three EBT Margin figures came in at 85.73% (Q1 2026), 62.83% (Q4 2025), and 48.59% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.40%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 41.95%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 23.05%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 18.99%
10 Sarepta Therapeutics 1.86 Bn 1.17 Bn 291.52 Mn 85.73%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 85.73%
Dec 31, 2025 -62.83%
Sep 30, 2025 -48.59%
Jun 30, 2025 25.14%
Mar 31, 2025 -287.64%
Dec 31, 2024 12.10%
Sep 30, 2024 7.28%
Jun 30, 2024 3.74%
Mar 31, 2024 10.02%
Dec 31, 2023 60.20%
Sep 30, 2023 -10.00%
Jun 30, 2023 -65.55%
Mar 31, 2023 -202.25%
Dec 31, 2022 199.35%
Sep 30, 2022 -123.41%
Jun 30, 2022 -108.00%
Mar 31, 2022 -473.28%
Dec 31, 2021 -66.31%
Sep 30, 2021 -25.29%
Jun 30, 2021 -57.64%
Mar 31, 2021 -113.93%
Dec 31, 2020 -837.93%
Sep 30, 2020 -873.10%
Jun 30, 2020 -579.58%
Mar 31, 2020 -131.39%
Dec 31, 2019 -234.73%
Sep 30, 2019 -127.32%
Jun 30, 2019 -291.79%
Mar 31, 2019 -87.99%
Dec 31, 2018 -167.83%
Sep 30, 2018 -98.19%
Jun 30, 2018 -147.76%
Mar 31, 2018 -54.52%
Dec 31, 2017 -45.11%
Sep 30, 2017 -99.50%
Jun 30, 2017 -180.39%
Mar 31, 2017 526.80%
Dec 31, 2014 -165,637.04%
Sep 30, 2014 -3,179.89%
Jun 30, 2014 -1,171.93%
Mar 31, 2014 -412.63%
Dec 31, 2013 -1,250.91%
Sep 30, 2013 -596.69%
Jun 30, 2013 -579.67%
Mar 31, 2013 -339.25%
Dec 31, 2012 -140.17%
Sep 30, 2012 -90.28%
Jun 30, 2012 -48.63%
Mar 31, 2012 -60.45%